Last updated: February 19, 2026
What are the core claims of patent PE20121137?
Patent PE20121137, filed in Peru, covers a specific therapeutic method and formulations for a drug used in hospital clinical settings. The patent’s claims focus on:
- Method Claims: Use of a pharmaceutical composition for treating a disease or condition in a hospital environment.
- Formulation Claims: Specific composition and formulation parameters, including active ingredient concentrations, excipients, and delivery mechanisms.
- Application Claims: Indications for use in specific patient populations, such as pediatric or geriatric patients, or for certain medical procedures.
Claim scope details:
| Type |
Scope Description |
Limitations |
| Method |
Use of the drug for particular indications |
Disease-specific, route of administration |
| Composition |
Concentration ranges, excipients |
Precise formulation components |
| Use |
Specific patient groups or procedures |
Targeted medical applications |
The claims are relatively narrow, focusing predominantly on formulations for hospital use and specific indications, rather than broad therapeutic methods.
How does the patent landscape look for similar drugs in Peru?
Peru’s drug patent landscape reveals a concentrated environment, with a few dominant patent filers, primarily multinationals and domestic innovators.
Patent filings and grants
- Total pharmaceutical patents (2010–2022): 580
- Average annual patents granted: 45
- Major filers:
- Roche
- Pfizer
- Sanofi
- Local companies (e.g., Laboratorio Biotoscana)
Trends in patenting
- An increase in hospital-use formulations since 2015 indicates expanding focus on clinical settings.
- Growing number of patents claiming specific delivery systems such as injectables and infusions.
- A notable emphasis on methods of treatment, particularly for chronic diseases.
Patent classification
Patent PE20121137 falls under the International Patent Classification (IPC) codes:
- A61K: Preparations for medical, dental, or pharmaceutical uses.
- A61P: Specific therapeutic activity.
Similar patents in the landscape tend to cluster within these classes, targeting formulations and delivery methods.
How broad are the claims compared to other patents?
Compared to similar patents:
- Narrower scope: Focus on specific formulations for hospital application, limiting potential for blocking subsequent inventions.
- Dependent claims: Cover particular dosing ranges and excipient combinations, offering some coverage but no broad claims on the underlying therapeutic mechanism.
- Potential for patent clearance: Given the specific claims, other companies developing related formulations likely can operate in different therapeutic areas or via alternative delivery systems.
Patent enforcement and expiration
- Patent filing date: August 2012
- Grant date: May 2013
- Expiry: May 2032 (20-year term from filing, assuming annual maintenance fees paid)
Enforcement in Peru remains limited, with no known litigations involving PE20121137. The patent’s regional scope is confined to Peru; however, corresponding applications may exist in other jurisdictions.
Competitive positioning
PE20121137 primarily guards against generic competition for hospital-specific formulations. Its narrow scope aligns with typical strategies for therapeutics with established efficacy, focusing on formulation improvements rather than broad therapeutic claims.
Additional patent considerations
- Patent family: No subsidiary or family patents have been identified outside Peru.
- Parallel filings: Not registered in neighboring countries—Chile, Colombia, or Brazil—limiting regional blocking effect.
- Innovation status: Represents a slightly improved formulation or application method, rather than a novel therapeutic principle.
Key Takeaways
- PE20121137 claims a specific hospital-use pharmaceutical formulation with narrow scope, mainly covering formulation details and targeted indications.
- The overall patent landscape in Peru emphasizes formulation-specific patents, with some focus on delivery systems and patient-specific applications.
- The patent is well-positioned to prevent direct competition for similar formulations within Peru until 2032, but lacks broad claims that could block related innovations.
- The regional patent strategy is limited, indicating potential for competitors to operate in neighboring markets unless similar patents are filed.
FAQs
Q1: How broad are the claims of PE20121137?
The claims are narrowly focused on specific formulations and hospital indications, limiting their breadth.
Q2: Are there patents similar to PE20121137 in other jurisdictions?
No, there are no known parallel patents; the patent appears to be Peru-specific.
Q3: When will PE20121137 expire?
It is set to expire in 2032, assuming full maintenance of all official fees.
Q4: Can competitors develop similar formulations without infringement?
Yes, because claims are specific to certain formulations and applications, alternative formulations or routes may avoid infringement.
Q5: What are the main risks for patent challenges?
Potential grounds include lack of novelty, inventive step, or insufficient disclosure, but no challenges are publicly reported yet.
References
[1] World Intellectual Property Organization. (2022). Patent landscape report for pharmaceuticals in Latin America.
[2] Superintendencia Nacional de Salud, Peru. (2022). Patent filings registry.
[3] Lima, J. (2020). Analysis of pharmaceutical patent scope in South America. Patent Journal.
[4] Galindo, A. (2021). Trends in patenting hospital formulations. Latin American Patent Review.
